Creso Pharma (ASX:CPH) - Adam Blumenthal
Adam Blumenthal
Source: EverBlu Capital
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Creso Pharma’s (CPH) target acquisition company Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin
  • Halucenex’s inventory now totals 22.3 grams, making it one of the largest holders of GMP-grade synthetic psilocybin in Canada
  • Psilocybin is a hallucinogenic substance people ingest from certain types of mushrooms that grow throughout Europe, South America, Mexico and the U.S.
  • This additional supply allows Creso Pharma and Halucenex to increase the number of participants in its proposed clinical trials
  • Furthermore, Creso Pharma will explore the potential to combine synthetic psilocybin with existing products to create new offerings
  • Shares in Creso Pharma are steady on the market this morning and are trading at 18 cents

Creso Pharma’s (CPH) target acquisition company Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin.

Halucenex’s inventory now totals 22.3 grams, making it one of the largest holders of GMP-grade synthetic psilocybin in Canada.

Psilocybin is a hallucinogenic substance people ingest from certain types of mushrooms that grow throughout Europe, South America, Mexico and the U.S.

This additional supply allows Creso Pharma and Halucenex to increase the number of participants in its proposed clinical trials which are scheduled to begin in Q3 2021.

Furthermore, Creso Pharma will explore the potential to combine synthetic psilocybin with existing products to create new offerings.

“Halucenex is now one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. This is a major development and opens a number of doors for Halucenex in medium and long term,” Non-Executive Chairman Adam Blumenthal said.

“Once it secures its licence from Health Canada, Halucenex will have the capacity to progress a number of research and development initiatives, which have the potential to unlock new drug delivery methods and combinations,” he added.

Shares in Creso Pharma are steady on the market this morning and are trading at 18 cents at 10:33 am AEST.

CPH by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…